Ruangvaravate N, Choojun K, Srikulsasitorn B, et al. - Researchers conducted this prospective, randomized, single-blinded study to examine ocular surface disease (OSD) changes after switching from preserved prostaglandin analogues monotherapy to preserved tafluprost, a recent prostaglandin F_2α derivative, and preservative-free (PF) tafluprost in primary open-angle glaucoma patients. Glaucoma patients treated with preserved prostaglandins (except tafluprost) monotherapy for at least 6 months, intraocular pressure ≤ 22 mmHg, and diagnosed of OSD [≥ 1 criterion; tear break-up time (TBUT) ≤ 10 seconds, corneal fluorescein staining ≥grade 1] in both eyes have been registered. Participants in the study were 30 patients (80% women; mean age: 61.2 ± 11.5 years). Treatment with PF-tafluprost improves TBUT better than preserved tafluprost, indicating that PF-tafluprost should be particularly advantageous for patients with preexisting OSD. In patients with glaucoma, less or no preservative anti-glaucoma eye drops can restore and improve the ocular surface.